Symbols / ZYME
ZYME Chart
About
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.86B |
| Enterprise Value | 1.54B | Income | -63.43M | Sales | 134.48M |
| Book/sh | 4.26 | Cash/sh | 3.37 | Dividend Yield | — |
| Payout | 0.00% | Employees | 263 | IPO | — |
| P/E | — | Forward P/E | 49.29 | PEG | — |
| P/S | 13.79 | P/B | 5.72 | P/C | — |
| EV/EBITDA | -25.18 | EV/Sales | 11.42 | Quick Ratio | 6.69 |
| Current Ratio | 6.94 | Debt/Eq | 5.91 | LT Debt/Eq | — |
| EPS (ttm) | -0.85 | EPS next Y | 0.49 | EPS Growth | — |
| Revenue Growth | 72.60% | Earnings | 2026-03-02 | ROA | -9.98% |
| ROE | -18.46% | ROIC | — | Gross Margin | -6.21% |
| Oper. Margin | -80.07% | Profit Margin | -47.16% | Shs Outstand | 74.84M |
| Shs Float | 73.88M | Short Float | 7.40% | Short Ratio | 4.04 |
| Short Interest | — | 52W High | 28.49 | 52W Low | 9.03 |
| Beta | 1.24 | Avg Volume | 801.32K | Volume | 198.82K |
| Target Price | $36.46 | Recom | Strong_buy | Prev Close | $23.63 |
| Price | $24.36 | Change | 3.09% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$36.46
Mean price target
2. Current target
$24.36
Latest analyst target
3. DCF / Fair value
$-10.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.36
Low
$30.00
High
$52.00
Mean
$36.46
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | init | Truist Securities | — → Buy | $40 |
| 2025-12-12 | up | Wells Fargo | Equal-Weight → Overweight | $33 |
| 2025-12-03 | init | Citizens | — → Market Outperform | $32 |
| 2025-11-21 | reit | B. Riley Securities | Buy → Buy | $40 |
| 2025-11-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $25 |
| 2025-11-19 | main | Stifel | Buy → Buy | $40 |
| 2025-11-18 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $17 |
| 2025-10-16 | main | JP Morgan | Overweight → Overweight | $23 |
| 2025-10-14 | up | HC Wainwright & Co. | Neutral → Buy | $26 |
| 2025-10-10 | init | B. Riley Securities | — → Buy | $30 |
| 2025-08-11 | main | Citigroup | Buy → Buy | $22 |
| 2025-07-03 | reit | HC Wainwright & Co. | Neutral → Neutral | $13 |
| 2025-05-20 | init | TD Securities | — → Buy | — |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $30 |
| 2025-03-10 | main | HC Wainwright & Co. | Neutral → Neutral | $13 |
| 2025-03-07 | main | Citigroup | Buy → Buy | $19 |
| 2024-12-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $14 |
| 2024-12-16 | up | JP Morgan | Neutral → Overweight | $18 |
| 2024-11-22 | reit | HC Wainwright & Co. | Neutral → Neutral | $12 |
- How Positive Zanidatamab Phase 3 Data And Buyback Plans At Zymeworks (ZYME) Have Changed Its Investment Story - simplywall.st ue, 24 Feb 2026 19
- Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews Fri, 20 Feb 2026 21
- A Look At Zymeworks (ZYME) Valuation After Recent Share Price Pullback - Yahoo Finance Wed, 28 Jan 2026 08
- Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative hu, 12 Feb 2026 08
- Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat Sun, 01 Feb 2026 08
- (ZYME) and the Role of Price-Sensitive Allocations - Stock Traders Daily Fri, 06 Feb 2026 08
- Zymeworks stock soars after positive Phase 3 results for cancer drug - Investing.com Mon, 17 Nov 2025 08
- Zymeworks (ZYME) Price Target Increased by 42.94% to 35.19 - Nasdaq Sat, 06 Dec 2025 08
- Zymeworks: A Lot Of Moving Parts (NASDAQ:ZYME) - Seeking Alpha Wed, 19 Nov 2025 08
- Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? - Yahoo Finance ue, 14 Oct 2025 07
- $ZYME stock is up 30% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- How Zymeworks Inc. (ZYME) Affects Rotational Strategy Timing - Stock Traders Daily ue, 17 Feb 2026 08
- What's Driving Zymeworks Stock Higher? - Nasdaq Mon, 12 Jan 2026 08
- Zymeworks Inc. (NASDAQ:ZYME) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance Sun, 09 Nov 2025 08
- Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up - simplywall.st ue, 18 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9560 | 216759.0 | — | Sale at price 22.67 per share. | MOORE PAUL ANDREW | Officer | — | 2026-01-12 00:00:00 | D |
| 1 | 17666 | nan | — | — | MOORE PAUL ANDREW | Officer | — | 2026-01-12 00:00:00 | D |
| 2 | 6120 | 138762.0 | — | Sale at price 22.67 per share. | HOLLYWOOD MARK | Chief Operating Officer | — | 2026-01-12 00:00:00 | D |
| 3 | 17666 | nan | — | — | HOLLYWOOD MARK | Chief Operating Officer | — | 2026-01-12 00:00:00 | D |
| 4 | 9310 | 211090.0 | — | Sale at price 22.67 per share. | SMITH JEFFREY T L MD, FRCP | Officer | — | 2026-01-12 00:00:00 | D |
| 5 | 17666 | nan | — | — | SMITH JEFFREY T L MD, FRCP | Officer | — | 2026-01-12 00:00:00 | D |
| 6 | 30424 | 689819.0 | — | Sale at price 22.67 per share. | GALBRAITH KENNETH HARRY | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 7 | 64000 | nan | — | — | GALBRAITH KENNETH HARRY | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 8 | 459 | 11099.0 | — | Stock Award(Grant) at price 24.18 per share. | PATTERSON LEONE D. CPA | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 9 | 20110 | 504699.0 | — | Sale at price 25.10 per share. | MOORE PAUL ANDREW | Officer | — | 2026-01-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -3.47M | -5.64K | 92.79K | 2.89K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.08 | 0.00 |
| NormalizedEBITDA | -92.11M | -119.52M | 141.34M | -207.28M |
| TotalUnusualItems | -16.51M | -1.19M | 1.15M | 1.19M |
| TotalUnusualItemsExcludingGoodwill | -16.51M | -1.19M | 1.15M | 1.19M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -122.69M | -118.67M | 124.34M | -211.84M |
| ReconciledDepreciation | 11.19M | 17.30M | 12.00M | 9.58M |
| EBITDA | -108.62M | -120.70M | 142.49M | -206.09M |
| EBIT | -119.82M | -138.01M | 130.49M | -215.67M |
| NetInterestIncome | 19.94M | 19.70M | 3.60M | 1.97M |
| InterestIncome | 19.94M | 19.70M | 3.60M | 1.97M |
| NormalizedIncome | -109.65M | -117.49M | 123.28M | -213.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -122.69M | -118.67M | 124.34M | -211.84M |
| TotalExpenses | 196.12M | 214.02M | 282.00M | 242.35M |
| TotalOperatingIncomeAsReported | -137.11M | -138.05M | 130.53M | -215.63M |
| DilutedAverageShares | 75.88M | 68.86M | 65.25M | 52.13M |
| BasicAverageShares | 75.85M | 68.86M | 65.19M | 51.55M |
| DilutedEPS | -1.62 | -1.72 | 1.90 | -4.61 |
| BasicEPS | -1.62 | -1.72 | 1.91 | -4.11 |
| DilutedNIAvailtoComStockholders | -122.56M | -118.67M | 124.11M | -240.38M |
| AverageDilutionEarnings | 140.00K | 0.00 | -231.00K | -28.53M |
| NetIncomeCommonStockholders | -122.69M | -118.67M | 124.34M | -211.84M |
| OtherunderPreferredStockDividend | 231.00K | 28.53M | ||
| NetIncome | -122.69M | -118.67M | 124.34M | -211.84M |
| NetIncomeIncludingNoncontrollingInterests | -122.69M | -118.67M | 124.34M | -211.84M |
| NetIncomeContinuousOperations | -122.69M | -118.67M | 124.34M | -211.84M |
| TaxProvision | 6.08M | -568.00K | 10.89M | -516.00K |
| PretaxIncome | -116.61M | -119.24M | 135.23M | -212.36M |
| OtherIncomeExpense | -16.73M | -894.00K | 1.11M | 1.31M |
| OtherNonOperatingIncomeExpenses | -218.00K | 291.00K | -42.00K | 118.00K |
| SpecialIncomeCharges | -17.29M | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 17.29M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 776.00K | -1.19M | 1.15M | 1.19M |
| NetNonOperatingInterestIncomeExpense | 19.94M | 19.70M | 3.60M | 1.97M |
| InterestIncomeNonOperating | 19.94M | 19.70M | 3.60M | 1.97M |
| OperatingIncome | -119.82M | -138.01M | 130.49M | -215.67M |
| OperatingExpense | 196.12M | 214.02M | 282.00M | 242.35M |
| ResearchAndDevelopment | 134.62M | 143.62M | 208.60M | 199.75M |
| SellingGeneralAndAdministration | 61.50M | 70.40M | 73.40M | 42.60M |
| GeneralAndAdministrativeExpense | 61.50M | 70.40M | 73.40M | 42.60M |
| OtherGandA | 35.40M | 48.10M | 49.60M | 24.70M |
| SalariesAndWages | 26.10M | 22.30M | 23.80M | 17.90M |
| TotalRevenue | 76.30M | 76.01M | 412.48M | 26.68M |
| OperatingRevenue | 76.30M | 76.01M | 412.48M | 26.68M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 68.96M | 70.12M | 63.06M | 46.63M |
| ShareIssued | 68.96M | 70.12M | 63.06M | 46.63M |
| TotalDebt | 18.51M | 26.72M | 28.11M | 32.33M |
| TangibleBookValue | 322.18M | 427.51M | 454.56M | 215.61M |
| InvestedCapital | 338.77M | 464.81M | 492.96M | 249.09M |
| WorkingCapital | 212.16M | 357.16M | 449.08M | 216.37M |
| NetTangibleAssets | 322.18M | 427.51M | 454.56M | 215.61M |
| CapitalLeaseObligations | 18.51M | 26.72M | 28.11M | 32.33M |
| CommonStockEquity | 338.77M | 464.81M | 492.96M | 249.09M |
| TotalCapitalization | 338.77M | 464.81M | 492.96M | 249.09M |
| TotalEquityGrossMinorityInterest | 338.77M | 464.81M | 492.96M | 249.09M |
| StockholdersEquity | 338.77M | 464.81M | 492.96M | 249.09M |
| GainsLossesNotAffectingRetainedEarnings | -6.95M | -6.60M | -6.66M | -6.66M |
| OtherEquityAdjustments | -6.95M | -6.60M | -6.66M | -6.66M |
| RetainedEarnings | -830.34M | -677.44M | -558.76M | -683.10M |
| AdditionalPaidInCapital | 152.25M | 142.27M | 151.61M | 197.71M |
| CapitalStock | 1.02B | 1.01B | 906.76M | 741.15M |
| CommonStock | 1.02B | 1.01B | 906.76M | 741.15M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 124.32M | 116.07M | 155.77M | 140.04M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 36.03M | 60.31M | 60.14M | 68.19M |
| OtherNonCurrentLiabilities | 895.00K | 1.61M | 2.98M | 2.65M |
| NonCurrentDeferredLiabilities | 19.37M | 36.24M | 32.38M | 34.51M |
| NonCurrentDeferredRevenue | 14.61M | 32.94M | 30.59M | 32.94M |
| NonCurrentDeferredTaxesLiabilities | 4.76M | 3.30M | 1.79M | 1.57M |
| LongTermDebtAndCapitalLeaseObligation | 15.77M | 22.46M | 24.79M | 31.02M |
| LongTermCapitalLeaseObligation | 15.77M | 22.46M | 24.79M | 31.02M |
| CurrentLiabilities | 88.29M | 55.76M | 95.62M | 71.85M |
| OtherCurrentLiabilities | 1.26M | 2.53M | 1.64M | 7.75M |
| CurrentDeferredLiabilities | 25.59M | 3.70M | 2.35M | 0.00 |
| CurrentDeferredRevenue | 25.59M | 3.70M | 2.35M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 2.74M | 4.26M | 3.32M | 1.31M |
| CurrentCapitalLeaseObligation | 2.74M | 4.26M | 3.32M | 1.31M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.22M | 6.15M | 14.37M | 3.35M |
| PayablesAndAccruedExpenses | 52.48M | 39.12M | 73.94M | 59.44M |
| CurrentAccruedExpenses | 47.20M | 31.10M | 47.16M | 52.03M |
| Payables | 5.28M | 8.02M | 26.79M | 7.42M |
| OtherPayable | 729.00K | 1.84M | 2.24M | |
| TotalTaxPayable | 1.38M | 1.81M | 17.08M | 0.00 |
| IncomeTaxPayable | 128.00K | 1.81M | 840.00K | 0.00 |
| AccountsPayable | 3.90M | 6.21M | 7.86M | 5.17M |
| TotalAssets | 463.09M | 580.88M | 648.73M | 389.13M |
| TotalNonCurrentAssets | 162.64M | 167.95M | 104.02M | 100.91M |
| OtherNonCurrentAssets | 8.92M | 7.57M | ||
| NonCurrentPrepaidAssets | 7.24M | 15.73M | 12.49M | |
| NonCurrentDeferredAssets | 4.38M | 3.62M | 1.35M | 4.28M |
| NonCurrentDeferredTaxesAssets | 4.38M | 3.62M | 1.34M | 3.07M |
| InvestmentsAndAdvances | 98.43M | 81.93M | 886.00K | 886.00K |
| GoodwillAndOtherIntangibleAssets | 16.59M | 37.30M | 38.40M | 33.48M |
| OtherIntangibleAssets | 4.58M | 25.28M | 26.38M | 21.47M |
| Goodwill | 12.02M | 12.02M | 12.02M | 12.02M |
| NetPPE | 34.32M | 37.54M | 47.65M | 49.77M |
| AccumulatedDepreciation | -17.83M | -20.66M | -13.30M | -14.06M |
| GrossPPE | 52.15M | 58.20M | 60.95M | 63.83M |
| Leases | 15.19M | 20.99M | 20.96M | 9.10M |
| ConstructionInProgress | 0.00 | 122.00K | 76.00K | 13.26M |
| OtherProperties | 30.00M | 29.50M | 32.63M | 35.31M |
| MachineryFurnitureEquipment | 6.96M | 7.58M | 7.28M | 6.16M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 300.45M | 412.93M | 544.71M | 288.22M |
| OtherCurrentAssets | 18.86M | 19.12M | 19.07M | 20.00M |
| PrepaidAssets | 20.00M | |||
| Receivables | 55.81M | 19.48M | 33.40M | 15.61M |
| AccountsReceivable | 55.81M | 19.48M | 33.40M | 15.61M |
| CashCashEquivalentsAndShortTermInvestments | 225.78M | 374.33M | 492.23M | 252.61M |
| OtherShortTermInvestments | 159.67M | 216.77M | 91.32M | 50.74M |
| CashAndCashEquivalents | 66.10M | 157.56M | 400.91M | 201.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -113.11M | -122.38M | 130.98M | -205.74M |
| RepurchaseOfCapitalStock | -30.05M | 0.00 | 0.00 | |
| RepaymentOfDebt | -14.00K | -21.00K | -14.00K | -17.00K |
| IssuanceOfCapitalStock | 0.00 | 76.09M | 107.53M | 0.00 |
| CapitalExpenditure | -3.07M | -4.08M | -13.12M | -13.29M |
| IncomeTaxPaidSupplementalData | 3.18M | 165.00K | 10.00M | |
| EndCashPosition | 66.10M | 157.56M | 400.91M | 201.87M |
| BeginningCashPosition | 157.56M | 400.91M | 201.87M | 242.04M |
| EffectOfExchangeRateChanges | 286.00K | 354.00K | 203.00K | -325.00K |
| ChangesInCash | -91.74M | -243.71M | 198.84M | -39.84M |
| FinancingCashFlow | -20.45M | 81.85M | 108.58M | 8.01M |
| CashFlowFromContinuingFinancingActivities | -20.45M | 81.85M | 108.58M | 8.01M |
| NetOtherFinancingCharges | -174.00K | -53.00K | -596.00K | -470.00K |
| ProceedsFromStockOptionExercised | 9.79M | 5.83M | 1.66M | 8.50M |
| NetCommonStockIssuance | -30.05M | 76.09M | 107.53M | 0.00 |
| CommonStockPayments | -30.05M | 0.00 | 0.00 | |
| CommonStockIssuance | 0.00 | 76.09M | 107.53M | 0.00 |
| NetIssuancePaymentsOfDebt | -14.00K | -21.00K | -14.00K | -17.00K |
| NetLongTermDebtIssuance | -14.00K | -21.00K | -14.00K | -17.00K |
| LongTermDebtPayments | -14.00K | -21.00K | -14.00K | -17.00K |
| InvestingCashFlow | 38.76M | -207.25M | -53.85M | 144.60M |
| CashFlowFromContinuingInvestingActivities | 38.76M | -207.25M | -53.85M | 144.60M |
| NetInvestmentPurchaseAndSale | 41.82M | -203.18M | -40.72M | 157.88M |
| SaleOfInvestment | 325.56M | 350.07M | 72.28M | 192.96M |
| PurchaseOfInvestment | -283.74M | -553.25M | -113.00M | -35.08M |
| NetIntangiblesPurchaseAndSale | -1.07M | -1.60M | -4.97M | -881.00K |
| PurchaseOfIntangibles | -1.07M | -1.60M | -4.97M | -881.00K |
| NetPPEPurchaseAndSale | -1.99M | -2.47M | -8.15M | -12.40M |
| PurchaseOfPPE | -1.99M | -2.47M | -8.15M | -12.40M |
| OperatingCashFlow | -110.04M | -118.30M | 144.11M | -192.45M |
| CashFlowFromContinuingOperatingActivities | -110.04M | -118.30M | 144.11M | -192.45M |
| ChangeInWorkingCapital | -30.95M | -25.55M | 4.01M | 393.00K |
| ChangeInOtherWorkingCapital | 3.56M | 3.70M | ||
| ChangeInOtherCurrentLiabilities | -8.31M | -3.66M | -3.74M | -26.00K |
| ChangeInPayablesAndAccruedExpense | 12.65M | -43.80M | 27.32M | 16.48M |
| ChangeInPayable | 12.65M | -43.80M | 27.32M | 16.48M |
| ChangeInAccountPayable | 14.34M | -44.77M | 26.48M | 16.48M |
| ChangeInTaxPayable | -1.68M | 970.00K | 840.00K | 0.00 |
| ChangeInIncomeTaxPayable | -1.68M | 970.00K | 840.00K | 0.00 |
| ChangeInPrepaidAssets | -2.49M | 4.29M | -2.06M | -15.79M |
| ChangeInReceivables | -36.36M | 13.92M | -17.51M | -266.00K |
| ChangesInAccountReceivables | -36.36M | 13.92M | -17.51M | -266.00K |
| OtherNonCashItems | -1.88M | 630.00K | -250.00K | 213.00K |
| StockBasedCompensation | 17.79M | 8.10M | 4.01M | 10.76M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 667.00K | 0.00 | -167.00K |
| AssetImpairmentCharge | 17.29M | 0.00 | 0.00 | 0.00 |
| DeferredTax | 691.00K | -757.00K | 1.94M | -953.00K |
| DeferredIncomeTax | 691.00K | -757.00K | 1.94M | -953.00K |
| DepreciationAmortizationDepletion | 11.19M | 17.30M | 12.00M | 9.58M |
| DepreciationAndAmortization | 11.19M | 17.30M | 12.00M | 9.58M |
| AmortizationCashFlow | 4.50M | 2.70M | 1.01M | 2.79M |
| AmortizationOfIntangibles | 4.50M | 2.70M | 1.01M | 2.79M |
| Depreciation | 6.70M | 14.60M | 10.99M | 6.79M |
| OperatingGainsLosses | -1.48M | -31.00K | -1.96M | -433.00K |
| NetForeignCurrencyExchangeGainLoss | -1.48M | -31.00K | -1.96M | -433.00K |
| NetIncomeFromContinuingOperations | -122.69M | -118.67M | 124.34M | -211.84M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ZYME
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|